Business Wire

Solnet Group Report: Proactive Safety Measures Protect Value of Solar Investments

Share

Solnet Group, a leading provider of smart solar energy solutions for commerce and industry, has released a new report addressing the critical issue of safety in rooftop solar installations. Titled "Safety and Security in C&I Rooftop PV,” the white paper outlines the most important considerations rooftop solar owners and installers can take to minimize risk and protect their investments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115915852/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

High-quality installers and components reduce risks later (Photo: Business Wire)

According to an audit by Clean Energy Associates, 97% of rooftop solar installations have major safety concerns. Solar panels that are improperly installed or maintained contribute not only to physical safety hazards such as fires but also to power outages and financial losses. A thorough understanding of these risks is necessary as more companies install rooftop solar to mitigate high energy costs and comply with new regulations. Against this backdrop, Solnet Group has compiled a review of risk-reducing technologies and best practices, focusing on how safety can impact the bottom line.

Safety in solar is highly relevant

The revised European Union’s Energy Performance of Buildings Directive will require rooftop solar on all new commercial buildings by 2026, and in renovated commercial buildings by 2027. Beyond this, up to 28% of European companies plan to voluntarily install a solar system within the next 3 years. With rapid growth in the number of solar installations, the risks grow as well. For businesses entering this market, a balance must also be found between upfront installation costs and the long-term operational costs of the array. By considering safety measures from the outset, companies can reduce both risks and costs by minimizing performance issues, keeping insurance premiums low, and mitigating disruptions.

Key findings

1. Safety is a prerequisite for investor confidence: A proactive approach to reducing risk enhances the lifespan of the array and ensures consistent energy generation. In turn, the project generates more value over its lifetime, creating assurance that rooftop solar systems are a viable investment.

2. High-quality installers and components reduce risks later: Comprehensive analyses of solar panel fires from both Germany and the UK indicate that installer error is one of the leading causes of fire incidents, illustrating the importance of a careful installation process. The right components can also mitigate fire risks and other hazards from electrical arcs. Power optimizers, which enable the panel field to be made voltage-free to facilitate firefighting and rescue operations, are increasingly required by insurers as a safety measure in solar installations.

3. Smart monitoring and maintenance tools contribute to a higher safety standard: Real-time monitoring and data analysis tools, coupled with automatic rapid shutdown, allow threats to be addressed right away. As a result, damage is minimized or even avoided, and the operator has a clearer overview of how the system is functioning. The international Zurich Insurance company has recently recommended smart solar systems in part due to the features of their panel-level power optimizers, which can be operated through remote control.

"The rationale behind Solnet’s focus on smart solar technology is not just efficiency; it's about ensuring our solar systems' quality, safety, and longevity. By incorporating features like continuous monitoring and protection mechanisms, we are elevating the safety standards of rooftop solar installations. Our report sheds light on the role of safety improvements in protecting investments and furthering the energy transition," says Arttur Kulvik, SVP Business Development at Solnet Group.

Solnet Group prioritizes safety in every stage of the design, installation, operations, and maintenance of its solar arrays. The company includes power optimizers and a suite of remote monitoring tools, including immediate fault detection alerts, as standard features in its smart solar systems.

The full report is available for download here.Solnet Group will also host a webinar on safety in commercial and industrial rooftop PV, together with representatives from SolarEdge and Zurich Insurance. Registration is open until January 18th.

The speakers at this webinar include Georg Stockschläder, RE Global Practice Leader Property at Zurich Insurance; Chris Voet, Key Accounts Director at Solar Edge; and Arttur Kulvik, SVP Business Development at Solnet Group.

About Solnet Group:

Established in 2014, Solnet Group is a rapidly growing solar energy company with units in the Netherlands, Germany, and Finland. In 2020, the company was listed as the 59th fastest-growing company in Europe on the Financial Times FT1000 list and ranked third in the energy sector. As early as 2016, Solnet Group received the Climate Solver award from WWF. Solnet Group offers comprehensive and high-quality services from consulting and planning to installation throughout Europe. To facilitate our clients' projects, we also provide services for project financing, solar plant maintenance, and repairs. Solnet Group's clientele includes major investment funds, shopping centers, retailers, as well as storage and logistics companies. For more information, visit www.solnet.group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Joanna Viileinen
Head of Marketing and Communications
Solnet Group
Joanna.viileinen@solnet.group
tel. +358 405383366

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye